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Backgrounds:  To understand  the clinical  impact  of PD-1/L1  expression  in  thymoma  (TM)  and  thymic
carcinoma  (TC),  we evaluated  the  frequency  of  PD-1/L1  expression  in  pre/post  chemotherapy  specimens
and  the  correlation  with  the  treatment  efﬁcacy.
Methods: The  expression  of  PD-1/L1  was  evaluated  using  immunohistochemistry  in patients  with  TM or
TC  treated  with  chemotherapy  between  2000  and  2014.  Using  formalin-ﬁxed,  parafﬁn-embedded  tissue
samples  and  a PD-L1  antibody,  the  expression  of PD-L1  in  the  TM and  TC specimens  was reported  in  terms
of the  H-score  (0–300),  with a score  ≥1  being  deﬁned  as  positive.  The  PD-1  expression  in the  tumor-
inﬁltrating  immune  cells  was  evaluated  based  on  the  intensity  (0–3)  of  staining  using a  PD-1  antibody.
The  objective  response  rate,  progression-free  survival,  and  the  difference  in  PD-1/L1  expression  between
the  pre/post  chemotherapy  were  evaluated.
Results:  Thirty  patients  (TM/TC  12/18)  were  evaluated.  PD-L1  positivity  were  TM/TC  67%/41%.  Within  the
PD-L1  positive/negative  populations,  the objective  response  rates  were  50%/0%  for  TM  and  14%/20%  for
TC. No  signiﬁcant  differences  in progression-free  survival  were  seen  according  to  the  PD-L1  expression
status.  Increases  in  both  the  PD-L1  and  PD-1  scores  were  observed  after  chemotherapy  in  six  serial
pre/post  chemotherapy  TM  specimens,  with  a mean  PD-L1  score  and  a median  PD-1  intensity  of  42/93,
and  0/2.5,  respectively.
Conclusions:  The  substantially  high  expression  of PD-L1  and  the increase  in PD-L1  and  PD-1  expression
after  chemotherapy  supports  anti-PD-1/L1  drugs  therapy  for TM  and  TC  as well  as  the development  of  a
l  use  
rs.  Pustrategy  for  its sequentia
© 2016  The  Autho
. Introduction
Thymic epithelial tumors (TETs) are rare neoplasms with an inci-
ence rate of 0.17 per 100,000 person-years [1]. The classiﬁcation
eveloped by the World Health Organization (WHO) divided TETs
ccording to an increasing degree of aggressiveness: thymomas
Abbreviations: TET, thymic epithelial tumor; TM,  thymoma; TC, thymic carci-
oma.
∗ Corresponding author at: Department of Thoracic Oncology, National Cancer
enter Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
E-mail address: hhorinou@ncc.go.jp (H. Horinouchi).
ttp://dx.doi.org/10.1016/j.lungcan.2016.05.007
169-5002/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).after  chemotherapy.
blished  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(TMs; types A, AB, B1, B2, and B3), and thymic carcinomas (TCs;
type C) in 2004. Patients with advanced TETs are candidates for
chemotherapy. The rarity and heterogeneity among TET subtypes
make it difﬁcult to develop a standard treatment. Today, platinum-
based regimens, especially carboplatin and paclitaxel, are widely
used for TCs because of its promising efﬁcacy and lower toxic-
ity compared with anthracycline therapy [2–4]. Sunitinib has been
the only molecular-targeted therapy which suggested efﬁcacy for
TCs [5], while other biological agents have demonstrated a lack
of activity against TETs [6]. Thus, there is a pressing need for the
development of newer treatment modalities for TETs.
In recent years, immunotherapy involving drugs such as
anti-programmed death 1 (PD-1) and its ligand (PD-L1) and
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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nti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have
hanged conventional chemotherapies, with improved treatment
ffects observed for melanoma, renal cell cancer, lung cancer,
nd other cancers [7–10]. Among the different tumor types, a
esponse to anti-PD-1/L1 drugs has been associated with PD-L1
umor expression, PD-L1 or PD-1 tumor inﬁltrating immune cell
TIIC) expression, and somatic mutations [11–15]. Moreover, clin-
cal studies have suggested that the tumor expression of PD-L1
as related to an increase in the objective response rate (ORR)
o anti-PD-1/L1 drugs [10,14]. Previous studies using immunohis-
ochemistry methods have demonstrated that PD-L1 is expressed
n TETs [16,17]. Thus, anti-PD-1/L1 drugs are candidates for the
reatment of TETs.
PD-1 is an immune-checkpoint protein for immune tolerance
hat inhibits T cell activation by binding with PD-L1 and other
igands. PD-1 modulates positive selection in the thymus and is con-
titutively expressed on thymic T-lymphocytes and upregulated on
ctivated T-cells, B-cells, myeloid cells [18–20], and TIICs in many
pithelial cancers. Once PD-L1 is expressed on tumor cells, the PD-
/L1 signaling pathway facilitates escape from antitumor immunity
y maintaining an immunosuppressive tumor microenvironment.
To evaluate the possibility of using anti-PD-1/L1 drugs to treat
atients with TETs, we  evaluated the presence of PD-1/L1 expres-
ion in specimens obtained before and after chemotherapy and the
orrelation between PD-1/L1 expression before chemotherapy and
he treatment efﬁcacy of chemotherapy in TETs.
. Materials and methods
.1. Patients and samples
Consecutive patients with pathologically conﬁrmed primary TM
r TC who underwent chemotherapy between 2000 and 2014 at
he National Cancer Center Hospital, Tokyo, Japan, were included.
he relevant clinical data were collected by retrospective reviews
f the patients’ charts. The institutional review board approved
he study (2010-0077). Pathological diagnosis was  based on WHO
lassiﬁcation on the 2004 (3rd) edition [21].
.2. Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue specimens
btained from either biopsies or surgeries were examined. Each
FPE block obtained from a surgical specimen was selected from
 centrally located area of the tumor that had been conﬁrmed to
ontain tumor cells using hematoxylin and eosin staining.
FFPE blocks were sectioned at a thickness of 4 m and deparaf-
nized, then subjected to immunohistochemical staining using
 previously described method [17] with a previously validated
abbit monoclonal PD-L1 antibody (E1L3N, 1:800, Cell Signal-
ng Technology, Danvers, MA)  and a PD-1 antibody (NAT105,
:100, Abcam, Cambridge, UK). For visualization of the antigen,
 peroxidase-labeled secondary antibody (EnVision/HRP system,
AKO, Carpinteria, CA) was applied. Furthermore, we used anti-
uman CD4 (4B12, Leica, Newcastle, UK) and anti-human CD8
4B11, Leica, Newcastle, UK) to detect TIICs.
Before scoring, specimens without a sufﬁcient amount of tumor
ells were excluded. Our criterion for the minimum amount of
umor cells required for an evaluation was a half ﬁeld of view
n a high-power ﬁeld (magniﬁcation ×400). Two  independent
bservers (Y.K and K.T) examined the stained slides in a blinded
ashion. Each of them evaluated the morphological features of
he thymic epithelial cells and determined the epithelial marker
xpression immunohistologically when they experienced difﬁculty
n distinguishing the epithelial components in TM,  especially typescer 99 (2016) 4–10 5
B1 and B2. A semiquantitative approach (H-score) [22] was  used
to evaluate the tumor expression of PD-L1. The staining percent-
ages (0%–100%) and the intensity of PD-L1 (0–3: 0, negative; 1,
very weak; 2, moderate; and 3, strong) in tumor cells were eval-
uated for two representative parts, and the mean PD-L1 expression
scores (0–300) were calculated by multiplying the percentage of the
stained tumor area by the staining intensity. For the PD-L1 expres-
sion scores, 3 (1%) was  used as the positive cutoff score. We used the
term PD-L1 “positive” only for specimens before chemotherapy to
evaluate the effects of chemotherapy and PD-L1 expression accu-
rately. A representative staining result is shown in Fig. 1. On the
other hand, a qualitative approach (0–3: 0, negative; 1, very weak;
2, moderate; and 3, strong) was used for evaluating the expression
of PD-1 on the most strongly stained area of the specimens because
of the heterogeneity of the PD-1 staining pattern. A PD-1 score of
1–3 was evaluated as “positive” only for specimens obtained before
chemotherapy.
2.3. Correlation between immunohistochemistry and
chemotherapy response
The treatment effect of the ﬁrst-line chemotherapy was  assessed
using the Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.1. The ORR for chemotherapy and overall survival (OS;
from the day of the start of chemotherapy to the date of death
from any cause or the date on which the patient was lost to follow
up) were analyzed by stratifying the specimens according to their
PD-1/L1 expression statuses. To evaluate the difference in PD-1/L1
expression before and after chemotherapy, TM specimens were
evaluated. However, serial specimens of TCs were not obtained.
2.4. Statistical analyses
The PD-L1 score and the PD-1 score were evaluated as contin-
uous variables, and the differences in these scores were analyzed
using the Wilcoxon signed rank test.
To avoid effects other than those related to chemother-
apy, patients who underwent surgery or radiation therapy after
chemotherapy were excluded from the PFS analysis. The PFS was
estimated according to the Kaplan-Meier method and was com-
pared between the two  groups using a log-rank test. A two-sided
P value ≤ 0.05 was considered statistically signiﬁcant. Statistical
analyses were performed with Stata version 13.0 (College Station,
Texas, USA).
3. Results
3.1. Patient characteristics
A total of 75 patients with TET underwent chemotherapy. As
for TM,  of the 17 patients who  received chemotherapy, 18 spec-
imens from 12 patients were available for analysis. As for TC, of
the 58 patients who received chemotherapy, 18 specimens from
18 patients with TC were available for analysis (Fig. 2). Three TM
and four TC surgical specimens had been previously evaluated for
PD-L1 expression in a tissue microarray analysis performed in our
previous study [17].
Thus, 36 specimens from 30 patients with TMs or TCs were
analyzed. The patient characteristics are shown in Table 1.
Of the 30 patients, 12 had TM (B1 = 1, B2 = 7, B3 = 3, oth-
ers = 1) and 18 had TC (squamous cell carcinoma = 12, neuroen-
docrine carcinoma = 2, adenocarcinoma = 1, others = 3). All the
patients received chemotherapy including one platinum com-
pound, and all chemotherapy regimens for TM were CODE
(cisplatin + vincristine + doxorubicin + etoposide).
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Fig. 1. Representative PD-L1 expression in thymic epithelial tumors.
The PD-L1 scores were 0 (Panel A), 90 (B), and 180 (C) at low magniﬁcation.
Membranous staining of the tumor cells was negative (D), moderate (E), and strong (F) at high magniﬁcation.
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Among ﬁve patients relapsed after surgery, no rebiopsies were
arried out. We evaluated specimens from surgeries.
Each specimen’s status (either from biopsy or from surgery, and
ither before or after chemotherapy), PD-L1 score, PD-L1 positiv-
ty, and PD-1 intensity and the treatment effect of chemotherapy
re shown in Table 2. In the analysis examining the efﬁcacy of
hemotherapy, 9 TM specimens and 17 TC specimens were ana-
yzed. Among patients with TM,  two patients had pure red cell
plasia, one had myoasthenia gravis, and one had myopathy other
han myoasthenia gravis.
.2. Tumor expression of PD-L1 in TMs  and TCsPD-L1 was detectable in the tumor epithelial cells, while TIICs
id not stain positive for PD-L1. The mean (range) of the PD-L1
cores was 51 (0–140) for the TMs  and 40 (0–180) for the TCs. TheTM = thymoma, TC = thymic carcinoma
median score was 30 for the TMs  and 0 for the TCs; 67% of the TMs
and 41% of the TCs were positive for PD-L1 (Table 2).
There was no signiﬁcant relationship in PD-L1 score and smok-
ing status (P = 0.648). Except for three patients with unknown
smoking status, the mean (range) of the PD-L1 scores was 49
(0–230) and PD-L1 was positive in 50% of past and current smok-
ers, while the mean (range) of the PD-L1 scores was 36 (0–150) and
PD-L1 was positive in 56% of never smokers.
As for the historical subtype of TC, the PD-L1 scores of two
patients with neuroendocrine carcinoma and one patient with ade-
nocarcinoma were all 0. The mean (range) of the PD-L1 scores was
47 (0–180) and 58% was  PD-L1 positive for 12 patients with squa-
mous cell carcinoma.
Comparing specimens’ status in TC, 75% (3/4) of surgery speci-
mens was  PD-L1 positive with the mean (range) score of 98 (0–180),
Y. Katsuya et al. / Lung Cancer 99 (2016) 4–10 7
Table  1
Patient characteristics.
N=30 %
Sex Male/Female 15/15 50/50
Age  (median [range]) 57 [31–75]
WHO  Type Thymoma 12 40
B1/B2/B3/others 1/7/3/1 8/59/25/8
Thymic carcinoma 18 60
Sq/NEC/Ad/others 12/2/1/3 67/11/5/17
Stage  III/IVa/IVb/Relapse 2/14/9/5 6/47/30/17
Chemotherapy Thymoma
CODE  12 40
Thymic carcinoma
CBDCA + PTX 11 37
Nedaplatin + PTX 4 13
CBDCA + GEM 1 3
CDDP + ETP 1 3
Nedaplatin 1 3
Stage = Masaoka Koga Stage, Sq = squamous cell carcinoma, NEC = neuroendocrine carcinoma, Ad = adenocarcinoma, CODE = cisplatin + vincristine + doxorubicin + etoposide,
CBDCA = carboplatin, PTX = paclitaxel, GEM = gemcitabine, CDDP = cisplatin, ETP = etoposide.
Table 2
PD-L1 and PD-1 expression and response to chemotherapy.
No. WHO  PD-L1 PD-1 Response Specimen status
Type Score +/− Score +/−
Thymoma 1 B2 10 + 0 − PR biopsy
2  B3 30 + 1 + PR biopsy
3  NOS 65 + 1 + PR biopsy
4  B2 0 − 0 − SD biopsy
5  B2 0 − 0 − SD biopsy
6  B2 0 − 0 − SD biopsy
7  B3 80 + 3 + SD biopsy
8  B2 130 + 0 − SD biopsy
9  B3 140 + 1 + SD biopsy
Mean score 51 Median score 0
Positivity 67% Positivity 44%
Thymic carcinoma 1 Sq 0 − 0 − PR biopsy
2  Sq 0 − 0 − PR biopsy
3  Sq 75 + 0 − PR biopsy
4  NEC 0 − 0 − SD biopsy
5  others 0 − 0 − SD biopsy
6  Sq 0 − 0 − SD biopsy
7  Sq 0 − 0 − SD biopsy
8  NEC 0 − 1 + SD biopsy
9  Ad 0 − 2 + SD biopsy
10  others 0 − 2 + SD surgery
11  Sq 85 + 1 + SD surgery
12  Sq 125 + 3 + SD surgery
13  others 150 + 2 + SD biopsy
14  Sq 0 − 0 − PD biopsy
15  Sq 20 + 1 + PD biopsy
16  Sq 45 + 0 − PD biopsy
17  Sq 180 + 1 + PD surgery
Mean score 40 Median score 0
Positivity 41% Positivity 47%
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[OS = thymoma/thymic carcinoma not otherwise speciﬁed, Sq = squamous cell c
D  = progressive disease, PRCA = pure red cell aplasia, MG  = myoasthenia gravis.
hile 31% (4/13) of biopsy specimens was PD-L1 positive with the
ean (range) score of 22 (0–150).
.3. Associations between PD-L1 expression and treatment effect
The ORRs for the TMs  and TCs were 33% and 18%, and the disease
ontrol rates (DCRs) were 100% and 76%, respectively. The ORR was
igher in the PD-L1 positive group (50% vs 0%) among the TMs, but similar trend was not observed among the TCs.
The median OS of the PD-L1 positive and negative groups among
he patients with TMs  were 77.1 months (95% CI, 41.7 months–NA
not achieved]) and 58.5 months (95% CI, 34.5 months–NA), respec-ma, NEC = neuro endocrine carcinoma, PR = partial response, SD = stable disease,
tively. No signiﬁcant differences were observed when analyzed
according to the PD-L1 expression status (P = 0.624). The median OS
of the PD-1 positive and negative groups among the patients with
TMs were 71.5 months (95% CI, 41.7 months–NA) and 78.1 months
(95% CI, 34.5 months–NA), respectively. No signiﬁcant differences
were observed when analyzed according to the PD-L1 expression
status (P = 0.689).
The median OS of the PD-L1 positive and negative groups among
the patients with TCs were 27.3 months (95% CI, 9.5 months–NA)
and 47.7 months (95% CI, 2.1–69.1 months), respectively. Again,
no signiﬁcant differences were observed when analyzed accord-
ing to the PD-1 expression status (P = 0.449). The median OS of the
8 Y. Katsuya et al. / Lung Cancer 99 (2016) 4–10
Table 3
Efﬁcacy of chemotherapy in the PD-1/L1 positive and negative groups in thymomas and thymic carcinomas.
PD-L1 PD-1
+ − + −
Thymoma ORR 3/6 (50%) 0/3 (0%) 2/4 (50%) 1/5 (20%)
DCR  6/6 (100%) 3/3 (100%) 4/4 (100%) 5/5 (100%)
mOS
(months)
77.1 58.5 71.5 78.1
[41.7–NA] [34.5–NA] [41.7–NA] [34.5–NA]
Thymic carcinoma ORR 1/7 (14%) 2/10 (20%) 0/8 (0%) 6/9 (33%)
DCR  4/7 (71%) 9/10 (90%) 6/8 (75%) 7/9 (78%)
mOS 27.3 47.7 30.9 47.6
O al, [95
P
w
C
o
(
3
s
s
t
3
a
o
a
o
s
m
2
i
s
c
1
4
p
b
I
t
T
P
a
i
e
t
0
m
e
c
f
i
[
s
W(months) [9.5–NA] 
RR = overall response rate, DCR = disease control rate, mOS  = median overall surviv
D-1 positive and negative groups among the patients with TCs
ere 30.9 months (95% CI, 9.5 months–NA) and 47.6 months (95%
I, 2.1–69.1 months), respectively. No signiﬁcant differences were
bserved when analyzed according to the PD-L1 expression status
P = 0.650) (Table 3).
.4. Tumor expression of PD-1 on TIICs
PD-1 was detectable in TIICs (scored) and other immune cells,
uch as in the stroma (not scored). The median (range) of the PD-1
cores was 0 (0–3) for the TMs  and 0 (0–3) for the TCs; 44% (4/9) of
he TMs  and 47% (8/17) of the TCs were positive.
.5. Expression of PD-L1 on tumor cells and PD-1 on TIICs before
nd after chemotherapy
Among the specimens obtained after chemotherapy, all (9/9)
f the TMs  and (1/1) TC expressed both PD-L1 in the tumor cells
nd PD-1 in the TIICs. Six patients with TM had serial specimens
btained both before and after chemotherapy. When the PD-L1
cores from before and after chemotherapy were compared, the
ean PD-L1 score increased from 42 (range 0–130) to 93 (range
5–180) after chemotherapy (P = 0.073). PD-L1 expression positiv-
ty increased from 67% to 100% in the same sample set. The PD-1
cores (range) for the TIICs increased from 0 (0–3) to 2.5 (2–3) after
hemotherapy (P = 0.070). PD-1 positivity increased from 33% to
00% in the same sample set (Table 4).
. Discussion
Here, we demonstrated that 67% of TMs  and 41% of TCs were
ositive for PD-L1 expression as determined using a validated anti-
ody (clone E1L3N) and specimens obtained before chemotherapy.
n six serial TM specimens, both the tumor expression of PD-L1 and
he TIIC expression of PD-1 increased to 100% after chemotherapy.
o our knowledge, this is the ﬁrst report regarding the positivity of
D-L1 and PD-1 in TETs using serial tissue samples obtained before
nd after chemotherapy.
The substantially high expression rate of PD-L1 in TETs was sim-
lar to the results of a previous study [17]. The frequency of PD-L1
xpression as determined using the antibody clone E1L3 N in other
umors was as follows: 15%–22% in non-small cell lung cancer [23],
% in small cell lung cancer [24], and 20% in malignant pleural
esothelioma [25]. Compared with these, the positivity of PD-L1
xpression in TETs was relatively high and could have important
linical implications for anti-PD-1/L1 drug treatment. In detail, the
requency of PD-L1 expression in TETs differed from that observed
n our previous study (23% [23/101] in TMs  and 70% [25/38] in TCs)
17]. The proportion of histological subtypes in TM might have
ome inﬂuence on the heterogeneity of the PD-L1 frequency. No
HO histological type A or AB specimens were included in this[2.1–69.1] [9.5–NA] [2.1–69.1]
% conﬁdential interval], NA = not achieved.
study, and the PD-L1 scores of types A and AB were relatively lower
than those of types B1–3 in previous studies [16,17]. Specimens in
more advanced stages with higher PD-L1 expression levels [17] may
also explain the difference in the PD-L1 frequency of the specimens
examined in these two studies.
From our study, PD-L1 expression was an inconclusive
biomarker as a predictive and prognostic factor of chemotherapy,
respectively. The absence of a consistent trend between the tumor
expression of PD-L1 and ORR does not suggest the usage of PD-L1
expression as a predictive marker. In published articles, a study on
melanoma has shown that the ORR of dacarbazine or paclitaxel
combined with carboplatin was relatively low in a PD-L1 posi-
tive group (9.1% vs 13.0%) [12], though a study on triple-negative
and HER-2 positive breast cancer has shown that the expression
of PD-L1 on TIICs was positively correlated with a response to
anthracycline plus taxane with carboplatin combination therapy
[26]. Our previous study analyzing a larger number of subjects also
showed that PD-L1 expression was  not a prognostic factor [17]. A
high level of tumor PD-L1 expression has been associated with a
poor prognosis in non-small cell lung cancer [27], renal cell carci-
noma [28], bladder cancer [29], and gastric cancer [30], while it was
associated with a better prognosis in malignant melanoma [12]. In
cervical cancer [31] and breast cancer [15], the expressions of PD-1
and PD-L1 on TIICs also played an important role in the effect of
chemotherapy.
The six serial TM specimens obtained before and after
chemotherapy demonstrated that the tumor expression of PD-L1
and the TIIC expression of PD-1 increased after chemotherapy.
Based on some studies, our results can be explained by the
“immunogenic cell death” of tumor cells after chemotherapy. Pre-
vious in vivo studies have shown an increase in PD-L1 expression
after chemotherapy or radiation therapy by enhancing the activa-
tion of CD8 T cells [32]. Furthermore, doxorubicin and paclitaxel,
which we used in our series, are known to induce immunogenic
cell death [33]. Unlike apoptosis, the immunogenic cell death of
tumor cells enhances the activation of dendritic cells, sequentially
activating T-cells to produce IFN-, which induces the expression
of PD-L1 on the tumor cells [34].
Our study had several limitations. First, the PD-L1 positivity
in the surgical specimens was  higher than that for the biopsy
specimens for TCs, and the difference in specimens might be a con-
founding factor when comparing the six serial biopsies in the TM
group. As a feature of our PD-L1 scoring method (H-score), as long
as the specimens contained a sufﬁcient amount of tumor cells, they
were regarded as being eligible for evaluation. Not a few specimens
from biopsies were excluded for validation because of this reason.
However, a notable number of biopsy specimens had scores as high
as those of the surgical specimens, as shown in Table 2. As a feature
of our PD-L1 scoring method (H-score), as long as the specimens
contained a sufﬁcient amount of tumor cells, they were regarded
as being eligible for evaluation. In non-small cell lung cancer, Kita-
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Table  4
Change in the PD-L1 and PD-1 expression after chemotherapy in serial specimens of thymomas.
No. WHO  type Before After Response OS (months)
PD-L1 PD-1 PD-L1 PD-1
Score Score Score Score
5 B2 0 0 25 3 SD 96.3+
4  B3 0 0 130 3 SD 34.5
1  B2 10 0 60 3 PR 153.6+
2  B3 30 1 45 2 PR 78.2
7  B2 80 3 180 2 SD 66.9
8  B2 130 0 115 2 SD 78.1+
Score (Mean) 42 (Median) 0 (Mean) 93 (Median) 2.5
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[
[Positivity 67% (4/6) 33% (2/6) 
R = partial response, SD = stable disease, OS = overall survival, + = patients who wer
ono et al. showed that even small samples from a needle biopsy
re adequate for evaluating PD-L1 expression in paired specimens
concordance, 92.4%) [35]. Specimens obtained through noninva-
ive procedures and enabling a precise pathological diagnosis are
eeded even more in this era of biomarker-driven therapy. Sec-
nd, the number of patients who could be evaluated was limited.
onsidering the rarity of TETs, however, this study deserves to be
eported as an initial study evaluating the relationship between
D-1/L1 expression and chemotherapy.
Of note, the experience in patients with a history of autoimmune
iseases is relatively limited, although patients with autoim-
une diseases were able to be treated relatively safely with the
nti-CTLA-4 ipilimumab on some case reports. However, the patho-
hysiology of dysimmune toxicities caused by anti-PD-1/L1 drugs
herapy is still not well understood. Treatment decision for patients
ith TM,  who have expected risks of autoimmune diseases, should
e carefully carried out [36].
Taken together, the present results conﬁrm the relatively high
roportion of PD-L1 expression in TET specimens among solid
umors, and the expression of PD-L1 in tumor cells and of PD-1
n TIICs after chemotherapy changed dynamically in a subset of
atients with TM.  These observations raise some practical consid-
rations for the development of anti-PD-1/L1 drugs therapy. The
ncrease in both PD-L1 and PD-1 expressions after chemotherapy
lso suggests the potential of new treatment combination strate-
ies, such as anti-PD-1/L1 drugs therapy after chemotherapy for
ETs.
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